Skip to search formSkip to main contentSkip to account menu

bevacizumab

Known as: Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody, Monoclonal Antibody Anti-VEGF 
A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also… 
National Institutes of Health

Related topics

Related topics

28 relations
16 ML bevacizumab 25 MG/ML Injection [Avastin]4 ML bevacizumab 25 MG/ML InjectionAngiogenesis InhibitionCAPOX-Bevacizumab Regimen

Broader (1)

Angiogenesis Inhibitors

Narrower (1)

Avastin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
P17.47COMPREHENSIVE PROTEOMIC PROFILING OF BEVACIZUMAB-RESISTANT GLIOBLASTOMA MULTIFORME
Drugs that impair tumour angiogenesis, i.e. therapeutic antibody anti-vascular endothelial growth factor, bevacizumab (BEV), are… 
2010
2010
Cancer esearch oenvironment and Immunology erential Effects of VEGFR-1 and VEGFR-2 Inhibition on R or Metastases Based on Host Organ Environment
Downloa ors induce new blood vessel growth primarily from host organ microvascular endothelial cells (EC), and vasculature… 
2010
2010
Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas
Angiogenesis is essential to tumour progression and a precise evaluation of angiogenesis is important for tumour early diagnosis… 
2009
2009
Colon perforation during antiangiogenic therapy for malignant glioma.
Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this… 
Highly Cited
2008
Highly Cited
2008
Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of…
4030 Background: The combination of Bev with 5-FU/FA and irinotecan or oxaliplatin is highly active in ACRC. A recent phase III… 
2006
2006
The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice
CEP-7055, a fully synthetic, orally active N,N-dimethylglycine ester of CEP-5214, a C3-(isopropylmethoxy)–fused pyrrolocarbazole… 
2004
2004
2,3,7,8-tetrachlorodibenzo-p-dioxin reduces myocardial hypoxia and vascular endothelial growth factor expression during chick embryo development.
BACKGROUND Previous research has demonstrated that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cardiomyocyte growth arrest… 
2004
2004
Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301).
3515 Background: The addition of bevacizumab (BV, Avastin) to IFL for untreated metastatic CRC produces survival benefit (Hurwitz… 
1999
1999
Vascular Endothelial Growth Factor (VEGF) in Crohn's Disease Increased Production by Peripheral Blood Mononuclear Cells and Decreased VEGF165 Labeling of Peripheral CD14+ Monocytes
Recently, increased serum levels of vascularendothelial growth factor (VEGF) have been shown inpatients with inflammatory bowel… 
1999
1999
Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury.
Lung development and repair of hyperoxic injury require closely regulated growth and regeneration of alveolar capillaries…